Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Randi, M.
Right arrow Articles by Fabris, F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Randi, M.
Right arrow Articles by Fabris, F
Haematologica, Vol 90, Issue 2, 261-262
Copyright © 2005 by Ferrata Storti Foundation

Letter

Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders

ML Randi, E Ruzzon, G Luzzatto, F Tezza, A Girolami, and F Fabris

The efficacy of hydroxyurea (HU) in myeloproliferative disorders is well documented. HU controls thrombocytosis both in polycythemia vera (PV) and in essential thrombocythemia (ET), while reducing the risk of thrombosis.1 Despite many anectodal reports, no evaluation of the prevalence and type of side effects of HU exists in large series of patients.




HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2005 by the Ferrata Storti Foundation.